NASDAQ
43.58USD
-3.41 (-7.26%)
We have scored 50 news catalysts on Nektar Therapeutics (NKTR) over the past 12 months. The biggest single-day move next to one of them came Nov 27, 2025, when NKTR closed +8.8%: “Rosen Law Firm Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation - AGL”. Coverage across the window leans negative (average ticker sentiment −0.55). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
1.15
52W range
33.4-109
Day range
43.51–47.13
Open
47.11
Prev close
46.99
Volume
2M
Avg volume
1M
Dividend
0.00
IPO
1994-05-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Nektar Therapeutics — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Nektar Therapeutics, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for NKTR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
